Wesley H Self1, Alan B Storrow2, Oliver Hartmann3, Tyler W Barrett2, Gregory J Fermann4, Alan S Maisel5, Joachim Struck3, Andreas Bergmann3, Sean P Collins2. 1. Department of Emergency Medicine, Vanderbilt University, Nashville, TN, USA. Electronic address: wesley.self@vanderbilt.edu. 2. Department of Emergency Medicine, Vanderbilt University, Nashville, TN, USA. 3. Sphingotec, GmbH, Hennigsdorf, Germany. 4. Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA. 5. Coronary Care Unit and Heart Failure Program, San Diego Veterans Affairs Medical Center, San Diego, CA, USA.
Abstract
OBJECTIVE: The objective was to evaluate the prognostic performance of a new biomarker, plasma bioactive adrenomedullin (bio-ADM), for short-term clinical outcomes in acute heart failure. METHODS: A multicenter prospective cohort study of adult emergency department (ED) patients suspected of having acute heart failure was conducted to evaluate the association between plasma bio-ADM concentration and clinical outcomes. The primary outcome was a composite of the following within 30 days: death, cardiac arrest with resuscitation, respiratory failure, emergency dialysis, acute coronary syndrome, hospitalization >5 days, and repeat ED visit or hospitalization. Prognostic accuracy was evaluated with a nonparametric receiver operating characteristic curve. In addition, a multivariable logistic regression model was constructed to assess the additive prognostic performance of bio-ADM while adjusting for other biomarkers routinely used clinically, including B-type natriuretic peptide, cardiac troponin I, creatinine, and sodium concentration. RESULTS: Two hundred forty-six patients were enrolled, including 85 (34.6%) patients with the primary outcome. Plasma bio-ADM concentrations were higher among patients who experienced the primary outcome (median, 80.5 pg/mL; interquartile range [IQR], 53.7-151.5 pg/mL) compared with those who did not (median, 54.4 pg/mL; IQR, 43.4-78.4 pg/mL) (P < .01). Area under the receiver operating characteristic curve was 0.70 (95% confidence interval, 0.63-0.75). After adjusting for the other biomarkers, plasma bio-ADM remained a strong predictor of the primary outcome (adjusted odds ratio per IQR change, 2.68; 95% confidence interval, 1.60-4.51). CONCLUSIONS: Bioactive adrenomedullin concentrations at the time of ED evaluation for acute heart failure were predictive of clinically important 30-day outcomes, suggesting that bio-ADM is a promising prognostic marker for further study.
OBJECTIVE: The objective was to evaluate the prognostic performance of a new biomarker, plasma bioactive adrenomedullin (bio-ADM), for short-term clinical outcomes in acute heart failure. METHODS: A multicenter prospective cohort study of adult emergency department (ED) patients suspected of having acute heart failure was conducted to evaluate the association between plasma bio-ADM concentration and clinical outcomes. The primary outcome was a composite of the following within 30 days: death, cardiac arrest with resuscitation, respiratory failure, emergency dialysis, acute coronary syndrome, hospitalization >5 days, and repeat ED visit or hospitalization. Prognostic accuracy was evaluated with a nonparametric receiver operating characteristic curve. In addition, a multivariable logistic regression model was constructed to assess the additive prognostic performance of bio-ADM while adjusting for other biomarkers routinely used clinically, including B-type natriuretic peptide, cardiac troponin I, creatinine, and sodium concentration. RESULTS: Two hundred forty-six patients were enrolled, including 85 (34.6%) patients with the primary outcome. Plasma bio-ADM concentrations were higher among patients who experienced the primary outcome (median, 80.5 pg/mL; interquartile range [IQR], 53.7-151.5 pg/mL) compared with those who did not (median, 54.4 pg/mL; IQR, 43.4-78.4 pg/mL) (P < .01). Area under the receiver operating characteristic curve was 0.70 (95% confidence interval, 0.63-0.75). After adjusting for the other biomarkers, plasma bio-ADM remained a strong predictor of the primary outcome (adjusted odds ratio per IQR change, 2.68; 95% confidence interval, 1.60-4.51). CONCLUSIONS: Bioactive adrenomedullin concentrations at the time of ED evaluation for acute heart failure were predictive of clinically important 30-day outcomes, suggesting that bio-ADM is a promising prognostic marker for further study.
Authors: Mihai Gheorghiade; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Barry H Greenberg; Christopher M O'Connor; Lilin She; Clyde W Yancy; James Young; Gregg C Fonarow Journal: Eur Heart J Date: 2007-02-19 Impact factor: 29.983
Authors: Mihai Gheorghiade; William T Abraham; Nancy M Albert; Barry H Greenberg; Christopher M O'Connor; Lilin She; Wendy Gattis Stough; Clyde W Yancy; James B Young; Gregg C Fonarow Journal: JAMA Date: 2006-11-08 Impact factor: 56.272
Authors: Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough Journal: N Engl J Med Date: 2002-07-18 Impact factor: 91.245
Authors: W Frank Peacock; Teresa De Marco; Gregg C Fonarow; Deborah Diercks; Janet Wynne; Fred S Apple; Alan H B Wu Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: S Eguchi; Y Hirata; H Iwasaki; K Sato; T X Watanabe; T Inui; K Nakajima; S Sakakibara; F Marumo Journal: Endocrinology Date: 1994-12 Impact factor: 4.736
Authors: Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer Journal: Eur J Heart Fail Date: 2021-10-10 Impact factor: 17.349
Authors: Salvatore Di Somma; Martin Magnusson; John Molvin; Amra Jujic; Silvia Navarin; Olle Melander; Giada Zoccoli; Oliver Hartmann; Andreas Bergmann; Joachim Struck; Erasmus Bachus Journal: Open Heart Date: 2019-07-03
Authors: Oscar H M Lundberg; Mari Rosenqvist; Kevin Bronton; Janin Schulte; Hans Friberg; Olle Melander Journal: PLoS One Date: 2022-04-28 Impact factor: 3.752
Authors: Oscar H M Lundberg; Maria Lengquist; Martin Spångfors; Martin Annborn; Deborah Bergmann; Janin Schulte; Helena Levin; Olle Melander; Attila Frigyesi; Hans Friberg Journal: Crit Care Date: 2020-11-04 Impact factor: 9.097
Authors: Henrike Arfsten; Georg Goliasch; Philipp E Bartko; Suriya Prausmüller; Georg Spinka; Anna Cho; Johannes Novak; Helmuth Haslacher; Guido Strunk; Joachim Struck; Martin Hülsmann; Noemi Pavo Journal: Br J Clin Pharmacol Date: 2020-07-20 Impact factor: 3.716